Prescribing information

 

I-WISh: IS AN EXPERT PHYSICIAN, PATIENT ADVOCACY DESIGNED AND ENDORSED, CROSS-SECTIONAL SURVEY THAT SOUGHT TO PROVIDE INSIGHTS ON THE BURDEN OF ITP AND ITS IMPACT ON PATIENT QoL USING A GLOBAL PATIENT AND PHYSICIAN SAMPLING FRAME

Objective

The aim of I-WISh is to investigate differences between patients’ and physicians’ perceptions of symptom burden, treatment goals and disease management.1

Number of respondents and method

  • 1507 patients and 472 physicians completed the survey from the 13 countries1
  • Patient numbers per country: Canada (n=61), China (n=286), Colombia (n=51), Egypt (n=0), France (n=87), Germany (n=82), India (n=65), Italy (n=74), Japan (n=56), Spain (n=48), Turkey (n=60), UK (n=120) and US (n=501)2
  • Patients completed a 30-minute online survey providing information on their demographic background, their experience of being diagnosed, current health state, symptoms experienced, the impact on QoL, as recorded by the ITP Life Quality Index (ILQI), and the emotional burden of the condition2

Patients

  • Mean (SD) patient age at survey completion was 47.1 (SD: 16.17) years1,2
  • Patients were recruited via patient association group (PAG) or treating physician2
  • Patients had been diagnosed with ITP for an average of 9.0 (SD, 10.78) years2
  • 64% of patients described their current health state as ≥5 using a 7-point Likert scale (7 is excellent health), whilst 32% described their health state as low (1–4 score, where 1 is very poor health)2

 

Abbreviations: ILQI, ITP Life Quality Index; ITP, immune thrombocytopenia; I-WISh, ITP World Impact Survey; PAG, patient association group; QoL, quality of life; SD, standard deviation.

References:

  1. Kruse A, et al. Presented at EHA 24th Annual Congress, Amsterdam, Netherlands, June 13–16, 2019. PF711.
  2. Data on file. I-WISh global study (REVDOF001). 
HCP19-C002i(1) June 2020.

For more information, refer to the REVOLADE® (eltrombopag olamine) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/7819/smpc

Legal Category: POM.

Aluminium blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/10/612/002 – 25 mg x 28 tablet pack £770, EU/1/10/612/005 – 50 mg x 28 tablet pack £1540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2310

 

×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]